drug
ASENAPINE MALEATE
Marketedupdated 3mo agoby Noven Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1indications
investigational
Schizophrenia
all catalysts(2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 6, 2026
56 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Oct 6, 2026patentUS 7741358*PED56d
- Oct 6, 2026patentUS 7741358*PED56d
- Oct 6, 2026patentUS 7741358*PED56d
- Oct 6, 2026patentUS 8022228*PED56d
- Oct 6, 2026patentUS 8022228*PED56d
- Oct 6, 2026patentUS 8022228*PED56d
- Apr 6, 2026compositionUS 7741358
- Apr 6, 2026compositionUS 7741358
- Apr 6, 2026compositionUS 7741358
- Apr 6, 2026compositionUS 8022228
- Apr 6, 2026compositionUS 8022228
- Apr 6, 2026compositionUS 8022228
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that